Advances in Our Understanding of ALK-Related Cancers: A Selection of Papers from the Joint Annual Meeting of the European Research Initiative for ALK-Related Malignancies (ERIA) and the European Union Marie Curie European Training Network ALKATRAS
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 November 2017) | Viewed by 81112
Special Issue Editors
Interests: laboratory animal pathology; molecular pathology; prostate cancer; ALCL
Interests: childhood Lymphoma; tyrosine kinase; genomic aberrations; super-enhancer; transcription factors; miRNA; non-coding RNA; drug screening; structure/function guided drug development; anaplastic large cell lymphoma
Special Issue Information
Dear Colleagues,
This Special Issue of Cancers will consist of selected papers from the “Joint 8th Annual Meeting of the European Research Initiative for ALK Related Malignancies (ERIA) and the 2nd Annual meeting of the European Union Marie Curie European Training network, ALK as a target of translational science (ALKATRAS) (www.erialcl.net and www.alkatras.erialcl.net)”, taking place in Cambridge (UK), on 28–29 September 2017. ERIA was established in 2009 to bring together scientists and clinicians with a shared interest in ALK-related cancers and to provide a platform for the exchange of scientific data, reagents and informal peer review. Largely, this is mediated through annual meetings and whilst originally solely a European enterprise, now incorporates research groups from across the World. In 2016, 14 research groups, all members of ERIA were awarded an EU Marie Curie European training Network, ALKATRAS which has enabled further collaboration through a network of 15 PhD students recruited from around the world and representing the next generation of ERIA members. As such, this international conference represents the major event for the scientific community working on ALK-related cancers and promises to be an exciting and exhilarating meeting. Particular attention is given to trainees, whereby students are encouraged to present their early, unpublished data to facilitate collaboration and advancement in this important area of research. This Special Issue will cover new and novel areas of research pertaining to ALK-related malignancies presented at this conference and therefore will represent state-of-the-art and up-to-date coverage of progress.
Dr. Suzanne Turner
Prof. Lukas Kenner
Dr. Olaf Merkel
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
